Format

Send to

Choose Destination
J Gastroenterol Hepatol. 2019 Jul 29. doi: 10.1111/jgh.14810. [Epub ahead of print]

Atorvastatin in combination with conventional antimicrobial treatment of Helicobacter pylori eradication: A randomized controlled clinical trial.

Author information

1
Gastroenterology and Hepatology Disease Research Center, Qom University of Medical Sciences, Qom, Iran.
2
Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
3
Department of Epidemiology, Qom University of Medical Sciences, Qom, Iran.

Abstract

BACKGROUND AND AIM:

Helicobacter pylori is one of the main causes of digestive diseases, which is difficult to treat and requires the administration of several antimicrobial agents. Considering the anti-inflammatory and antibacterial effect of atorvastatin, the present study aimed at adding this agent to a four-drug regimen in order to eradicate H. pylori.

METHODS:

A total of 220 patients with H. pylori infection were included in the current randomized controlled clinical trial. In the current study, 110 patients in the control group received a 14-day regimen of amoxicillin, clarithromycin, bismuth, and esomeprazole, and 110 patients in the intervention group received 40 mg of atorvastatin daily plus the antibiotic regimen for 14 weeks. The treatment results were evaluated 1 month later using H. pylori stool antigen test. Data were collected using checklist and analyzed using chi-squared and Fisher's exact tests with spss version 18.

RESULTS:

Helicobacter pylori eradication rate in the intervention and control groups was 78.18% and 65.45%, respectively (P = 0.025), and there was a significant difference in terms of non-ulcer dyspepsia between the groups (P = 0.049), but there was no significant difference in age, gender, and body mass index between the two groups (P < 0.05).

CONCLUSION:

The present study results showed that adding atorvastatin to the four-drug regimen of omeprazole, clarithromycin, bismuth, and amoxicillin is effective in the eradication of H. pylori. Also, the addition of atorvastatin to H. pylori eradication therapy is more effective in patients with non-ulcer dyspepsia.

KEYWORDS:

Atorvastatin; Digestive diseases; Eradication; Helicobacter pylori

PMID:
31359499
DOI:
10.1111/jgh.14810

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center